trial

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

NCTId NCT02019329
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 32 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2014-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
32 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2014-01
Primary completion
2014-08
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
RO5545965Risperidone

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
32
Phase
PHASE1
Primary Completion Date
2014-08
Status
COMPLETED
relationships
The graph out of here
drug
RO5545965
drug
Risperidone
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication